Mark J Foley
CIK 1529196 · President & CEO · last filed 2026-06-23
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$9.91M
Companies
4
Total Filings
129
Lifetime Open-Market Net
-$30.04M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| GKOS | Director | 60,267 | $161.75 | $9.75M | -$2.92M | 19 | 2026-06-23 |
| Revance Therapeutics, Inc. (RVNC) Delisted | President & CEO | 27,933 | $3.65 | $102.0K | -$5.60M | 34 | 2025-02-06 |
| SIBN | Director | 8,797 | $18.49 | $162.7K | $0 | 2 | 2020-06-18 |
| Zeltiq Aesthetics Inc (ZLTQ) Delisted | President and CEO | 0 | — | — | -$21.52M | 67 | 2017-04-28 |
Recent Filings · Page 2 of 13
129 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-06-03 | GKOS | Grant (A) | +1,716 | $0 | EDGAR |
| 2024-03-19 | Revance Therapeutics, Inc. (RVNC) Delisted | Tax (F) | −20,533 | -$108.9K | EDGAR |
| 2024-03-08 | Revance Therapeutics, Inc. (RVNC) Delisted | Buy (P) | +30,000 | $209.4K | EDGAR |
| 2024-03-04 | Revance Therapeutics, Inc. (RVNC) Delisted | Grant (A) | +70,750 | $0 | EDGAR |
| 2024-02-26 | GKOS | Mixed | +5,440 | -$350.7K | EDGAR |
| 2024-02-23 | GKOS | Notice (144) | −4,560 | -$423.5K | EDGAR |
| 2024-02-02 | Revance Therapeutics, Inc. (RVNC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-01-03 | Revance Therapeutics, Inc. (RVNC) Delisted | Grant (A) | +264 | $2.0K | EDGAR |
| 2023-08-15 | Revance Therapeutics, Inc. (RVNC) Delisted | Mixed | +74,079 | -$908.9K | EDGAR |
| 2023-08-04 | Revance Therapeutics, Inc. (RVNC) Delisted | Sell (S) | −26,279 | -$593.2K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.